The first company has provided a potential out-of-pocket price for patients who seek access through the recently passed federal Right-to-Try legislation and it’s not cheap. BrainStorm Cell Therapeutics could charge more than $300,000 for its Phase III experimental amyotrophic lateral sclerosis therapy NurOwn.
ALS patients were some of the most vocal supporters of the Right-to-Try legislation. Following the legislation having been signed into law, BrainStorm issued a press release noting that it has received numerous Right-to-Try requests from patients for its Phase III experimental amyotrophic lateral sclerosis therapy NurOwn. In an interview with Bloomberg, Chaim Lebovits, chief executive officer of BrainStorm, said his company was exploring the option of the new law with a small for-profit enterprise up for consideration. Lebovits said the company would consider including doctors who participated in the company’s clinical trials to seek access to NurOwn for patients who are not part of the trial process. But, the company will not give away doses of its ALS treatment. The cost could be expensive for patients and it is unlikely that any insurance company would cover the cost of an experimental drug.
Lebovits told Bloomberg that there has to be an incentive for BrainStorm to manufacture and provide additional doses of NurOwn to non-trial patients. In his interview with Bloomberg, he noted that companies are not “nongovernmental organizations that help provide care to impoverished countries.”